Metformin, the widely prescribed type 2 diabetes medication taken by roughly 150 million people worldwide, has become the most-studied repurposed drug in cancer research. Researchers have been investigating whether this cheap, well-tolerated pill could do double duty against prostate, breast, and gynecologic cancers, among others. The results so far are genuinely mixed — some trials show no significant benefit, while specific patient subgroups appear to respond differently — and that complexity is exactly what makes this story worth following closely, especially for those of us interested in how the medical establishment rethinks existing tools. But metformin is not alone.
Statins, beta blockers, antiparasitic drugs, and even aspirin are all being investigated as potential cancer-fighting agents. For readers of a brain health site, the connection is not abstract: two of these drug classes — statins and metformin — are already part of the daily regimen for millions of older adults managing cardiovascular risk and diabetes, conditions that overlap heavily with dementia risk. And antiparasitic drugs like mebendazole are now in early clinical trials for glioma, a form of brain cancer. This article walks through what the research actually shows, where the hype outpaces the evidence, and what any of this means for people already taking these medications.
Table of Contents
- Which Common Drugs Are Being Repurposed to Fight Cancer, and Why?
- What Does the Clinical Evidence Actually Show for Metformin and Cancer?
- Statins, Beta Blockers, and the Combination Question
- Antiparasitic Drugs and Brain Cancer — What Should Patients Know?
- Why Promising Drugs Fail in Trials — and What That Means for Patients
- Aspirin and the Drugs Closest to Mainstream Cancer Use
- Where Drug Repurposing Goes From Here
- Conclusion
- Frequently Asked Questions
Which Common Drugs Are Being Repurposed to Fight Cancer, and Why?
Drug repurposing — sometimes called repositioning — takes medications with pre-established FDA safety and pharmacokinetic profiles and tests them against new diseases. The appeal is straightforward: developing a new cancer drug from scratch costs billions and takes over a decade. Repurposing an existing drug with a known safety record can cut both the timeline and the cost dramatically. The National Cancer Institute’s Division of Cancer Prevention actively tracks the repurposing of common medications for cancer prevention, which signals that this is not a fringe idea. The drugs generating the most attention fall into a few categories. Metformin leads the pack, with dozens of clinical trials completed or underway. Statins, the cholesterol-lowering drugs taken by tens of millions, have demonstrated potential to kill cancer cells and boost immune responses.
Beta blockers like propranolol, typically prescribed for high blood pressure and anxiety, have shown improved outcomes in certain blood cancers. Antiparasitic drugs — mebendazole, fenbendazole, and ivermectin — are attracting intense public interest, though clinical evidence remains thin. And aspirin, along with metformin, is considered closest to mainstream integration as a repurposed cancer drug as of 2026. The reason these drugs are plausible cancer candidates varies by mechanism. Metformin appears to influence cellular energy metabolism and insulin signaling pathways that tumors exploit. Statins interfere with the mevalonate pathway, which cancer cells rely on for growth. Antiparasitics disrupt microtubule dynamics — the same structural scaffolding that cancer cells need to divide. None of these drugs were designed with cancer in mind, but biology does not care about a drug’s original label.
What Does the Clinical Evidence Actually Show for Metformin and Cancer?
The honest answer is that metformin’s track record in rigorous cancer trials has been disappointing more often than not. The MAST Trial, a randomized, double-blind, placebo-controlled study of 408 men with low-risk prostate cancer, found that metformin did not significantly reduce disease progression after 36 months of follow-up. There were 70 progressions in the metformin group compared with 74 in the placebo group — essentially no meaningful difference. More troubling, metformin was associated with increased pathologic progression among obese patients with a BMI of 30 or higher, the very population many assumed would benefit most. The STAMPEDE Trial looked at metformin in a more aggressive setting — metastatic prostate cancer. Adding metformin to standard hormone therapy did reduce some metabolic side effects: patients gained less weight (2 kilograms versus 4.4 kilograms at two years) and had lower cholesterol and blood sugar.
However, the trial did not show a statistically significant overall survival benefit. There was some suggestion that men with the highest-risk prostate cancer may benefit, but this needs further investigation before anyone should act on it. The story is similarly nuanced for other cancers. A subgroup analysis from a large randomized controlled trial in breast cancer suggested potential benefits of metformin in improving overall and disease-free survival among HER2-positive patients specifically, but not other phenotypes. And a 2026 meta-analysis of randomized controlled trials found that metformin combined with standard therapy did not significantly improve progression-free or overall survival in gynecologic malignancies. The pattern here matters: observational studies often look promising, but when subjected to the rigor of controlled trials, the benefits frequently shrink or vanish. Anyone who tells you metformin is a proven cancer treatment is ahead of the evidence.
Statins, Beta Blockers, and the Combination Question
Statins occupy an interesting position in this landscape because they are already prescribed to a huge portion of the older adult population. Research has shown they can improve survival in head and neck cancers, and there is growing interest in how they interact with other repurposed drugs. One particularly striking finding: when statins were combined with metformin, the combination was associated with a greater than 50 percent reduction in cancer mortality in patients with high-grade prostate cancer, compared with statins alone. That is a dramatic number, but it comes from observational data rather than a randomized controlled trial, so it needs to be interpreted with caution. Beta blockers represent another avenue. Propranolol, a nonselective beta blocker that many older adults take for blood pressure or heart rhythm management, has shown improved progression-free survival and overall survival in patients with multiple myeloma.
The proposed mechanism involves blocking stress hormones — specifically catecholamines — that tumors may exploit to promote their own blood supply and suppress immune responses. For someone already taking propranolol for a cardiac condition, this is potentially encouraging news, but it is not a reason to start the drug solely for cancer prevention. The broader lesson from these findings is that most repurposed drugs cannot be used as single agents against cancer. Their potential seems to lie in combination — with standard chemotherapy, with each other, or with targeted therapies. This makes clinical trial design more complicated and means that definitive answers will take longer to arrive. For patients and families hoping for a simple add-on to existing treatment, the reality is that we are still in the early innings of understanding which combinations work, for whom, and at what stage of disease.
Antiparasitic Drugs and Brain Cancer — What Should Patients Know?
The antiparasitic drugs — mebendazole, fenbendazole, and ivermectin — have generated enormous grassroots interest, particularly online. These drugs disrupt cancer cell growth by targeting microtubule dynamics, inducing apoptosis (programmed cell death), and potentially enhancing anticancer immune responses. As of March 2026, there are 590 compiled anecdotal case reports of fenbendazole, ivermectin, or mebendazole use in cancer patients. Those reports are not controlled trials, and anecdotal evidence, no matter how voluminous, cannot establish that a drug works. People who improve might have improved anyway; people who do not improve are less likely to share their stories.
What makes this category relevant to brain health readers is that the only early-phase clinical trials currently underway for these drugs are both in glioma — brain cancer. Mebendazole in particular has received attention from the ReDO (Repurposing Drugs in Oncology) project, which has reviewed its anticancer mechanisms in detail. Florida has committed 60 million dollars to study repurposed antiparasitics in health and disease, which will help generate the kind of controlled data that is currently missing. However, there is a critical distinction between “shows promise in lab studies” and “works in human patients.” Many drugs that kill cancer cells in a dish fail in the body because they cannot reach the tumor at sufficient concentrations, or because side effects become unacceptable at the doses needed, or because the human immune system complicates the picture in ways that cell cultures cannot predict. Patients with brain tumors or their caregivers who are considering these drugs should discuss them with their oncology team rather than self-medicating based on online case reports.
Why Promising Drugs Fail in Trials — and What That Means for Patients
One of the most frustrating patterns in drug repurposing is the gap between observational data and randomized trial results. Metformin looked very promising based on population-level studies showing that diabetic patients on metformin had lower cancer rates than those on other diabetes drugs. But observational studies are riddled with confounders — metformin users may be healthier in other ways, diagnosed earlier, or managed more aggressively. When the MAST and STAMPEDE trials controlled for these variables, the cancer-specific benefits largely evaporated. This does not mean drug repurposing is a dead end.
It means the field is maturing beyond early enthusiasm. The metformin breast cancer finding — that HER2-positive patients may benefit even though the overall population does not — illustrates a crucial shift toward precision medicine. Rather than asking “does metformin fight cancer,” researchers are now asking “which patients, with which tumor characteristics, at which stage, might benefit from metformin as an addition to standard treatment.” That is a harder question to answer, and it requires larger, more carefully designed trials with biomarker-driven subgroup analyses. For patients and caregivers, the practical warning is this: do not stop or start any medication based on preliminary cancer repurposing data without consulting your physician. The MAST Trial’s finding that metformin may actually worsen outcomes in obese prostate cancer patients is a sobering reminder that even safe, well-known drugs can behave unpredictably in new contexts. The metabolic benefits that metformin showed in the STAMPEDE Trial — less weight gain, better cholesterol — may still justify its use in certain cancer patients, but that is a decision for an oncologist to make with full knowledge of the patient’s profile.
Aspirin and the Drugs Closest to Mainstream Cancer Use
Aspirin deserves a brief mention because, alongside metformin, it is considered the repurposed drug closest to mainstream integration for cancer prevention as of 2026. The evidence base for aspirin in colorectal cancer prevention is particularly strong, and ongoing trials are exploring its role in other tumor types. For older adults already taking low-dose aspirin for cardiovascular protection, the potential cancer-preventive benefit represents a meaningful bonus — though the bleeding risks that come with long-term aspirin use must be weighed carefully.
The broader trajectory here is encouraging. Drug repurposing leverages pre-established safety profiles, which means that even when a drug does not show dramatic anticancer effects, we already know its side effect profile intimately. That is a genuine advantage over novel compounds entering Phase 1 trials. For the dementia and brain health community specifically, the overlap between cardiovascular risk management drugs (statins, aspirin, metformin, beta blockers) and cancer repurposing candidates is worth noting — many older adults are already taking one or more of these medications, and future research may clarify whether those medications are providing benefits beyond their original purpose.
Where Drug Repurposing Goes From Here
The next several years will be critical. Florida’s 60-million-dollar investment in antiparasitic drug research, ongoing metformin trials with biomarker-driven subgroup analyses, and the NCI’s continued tracking of repurposing candidates all suggest that the field will generate substantially more data soon. The key question is not whether any single drug will become a cancer cure — none of them will — but whether combinations of cheap, well-tolerated drugs can meaningfully improve outcomes when added to standard therapies.
For people living with dementia risk factors, or caring for someone who is, the intersection of these medication classes with both brain health and cancer research is a space worth watching. The same metabolic pathways that connect diabetes to dementia also appear to connect diabetes to cancer. As researchers untangle these relationships, the medications that older adults already take may turn out to be doing more — or, in some cases, less — than we currently assume.
Conclusion
Metformin remains the most-studied repurposed drug for cancer, but the clinical trial evidence so far is more humbling than the early hype suggested. It has not demonstrated broad anticancer efficacy, though specific subgroups — HER2-positive breast cancer patients, possibly the highest-risk prostate cancer patients — may benefit. Statins, beta blockers, antiparasitic drugs, and aspirin each have their own emerging evidence base, with antiparasitics being the furthest from clinical validation despite intense public interest.
The takeaway for patients and caregivers is to stay informed but stay grounded. Drug repurposing is a legitimate scientific strategy, not a miracle shortcut. Talk to your medical team before making any medication changes based on cancer repurposing research. The drugs in your medicine cabinet may one day have expanded labels, but that day has not arrived yet — and acting prematurely on incomplete evidence carries its own risks.
Frequently Asked Questions
Is metformin a proven cancer treatment?
No. While metformin is the most-studied repurposed drug for cancer, rigorous randomized controlled trials have generally not shown statistically significant improvements in cancer progression or overall survival for the general population. Some specific subgroups, such as HER2-positive breast cancer patients, may benefit, but this requires further validation.
Should I start taking metformin to prevent cancer?
Not without consulting your doctor. The MAST Trial found that metformin was associated with increased pathologic progression in obese prostate cancer patients, demonstrating that even well-known drugs can have unexpected effects in new contexts. Any decision to use metformin outside its approved indication should involve your oncologist or primary care physician.
Are fenbendazole and ivermectin effective against cancer?
There is no controlled clinical trial evidence proving their efficacy in cancer patients. As of March 2026, there are 590 compiled anecdotal case reports, but anecdotal evidence cannot establish that a drug works. Only two early-phase clinical trials are underway, both in glioma. These drugs should not be self-administered for cancer without medical supervision.
Can statins help fight cancer?
Statins have shown potential to kill cancer cells and improve survival in head and neck cancers. When combined with metformin, they were associated with a greater than 50 percent reduction in cancer mortality in high-grade prostate cancer patients. However, these findings come primarily from observational studies and need confirmation in randomized trials.
Why do promising repurposed drugs often fail in clinical trials?
Observational studies are subject to confounders — patients taking certain drugs may differ from those who do not in ways that affect cancer outcomes. When randomized controlled trials eliminate these confounders, the apparent benefits often diminish or disappear. This is a normal part of the scientific process, not a sign that repurposing is flawed.
Is there a connection between cancer drug repurposing and brain health?
Yes, indirectly. Many drugs being studied for cancer repurposing — metformin, statins, beta blockers — are commonly taken by older adults managing conditions that also increase dementia risk. Mebendazole is in early clinical trials specifically for glioma, a brain cancer. The metabolic pathways linking diabetes, cardiovascular disease, dementia, and cancer are an active area of research.
